| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/29/2007 | WO2005109987A9 3-(((4-phenyl)-piperazine-1-yl)-alkyl)-3-alkyl-1, 3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders |
| 03/29/2007 | WO2002056916A8 Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients |
| 03/29/2007 | US20070074295 Schizophrenia related gene |
| 03/29/2007 | US20070073061 Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them |
| 03/29/2007 | US20070072917 Substituted 2-aminotetralin for the treatment of depression |
| 03/29/2007 | US20070072886 Method of treating movement disorders using barbituric acid derivatives |
| 03/29/2007 | US20070072872 Treating sexual desire disorders with flibanserin |
| 03/29/2007 | US20070072865 Bicyclic piperazine compound and use thereof |
| 03/29/2007 | US20070072853 Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof |
| 03/29/2007 | US20070072835 Method of preparing and use of prodrugs of betulinic acid derivatives |
| 03/29/2007 | US20070072820 Gene expression inhibition; sustained release; for reduction of neuronal cell death, inflammation, and scar formation; improves wound healing, skin rejuvenation and thickening |
| 03/29/2007 | US20070072819 Gene expression inhibition; sustained release; for reduction of neuronal cell death, inflammation, and scar formation; improves wound healing, skin rejuvenation and thickening |
| 03/29/2007 | US20070072807 Method of screening compounds |
| 03/29/2007 | US20070072291 Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
| 03/29/2007 | US20070072261 Nucleic acids encoding PAK5 polypeptidesm and methods of use thereof |
| 03/29/2007 | US20070072236 Novel type II Na/Pi cotransporters and type II Na/Pi cotransporter expression regulatory factors |
| 03/29/2007 | US20070071752 Sphingosine kinase enzyme |
| 03/29/2007 | US20070069416 Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| 03/29/2007 | DE202006013518U1 Mittel zur Behandlung von neuroendokrinen gesundheitlichen Störungen Agents for the treatment of health disorders neuroendocrine |
| 03/29/2007 | CA2800945A1 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration |
| 03/29/2007 | CA2623472A1 Use of inhibitors of the na+/h+ exchanger, subtype 5 (nhe5), to improve memory retention |
| 03/29/2007 | CA2623304A1 Medicine, food and drink or feed containing sphingomyelin |
| 03/29/2007 | CA2623092A1 2-aminoalcohols for the treatment of neurodegenerative diseases |
| 03/29/2007 | CA2622741A1 2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists |
| 03/29/2007 | CA2621062A1 Alkyl sulfoxide quinolines as nk-3 receptor ligands |
| 03/29/2007 | CA2620235A1 Association of .beta.3 receptor agonist and monoamine reuptake inhibitors, pharmaceutical composition containing same and therapeutic use thereof |
| 03/29/2007 | CA2615897A1 Compounds and methods for treatment of amyloid-beta-peptide related disorders |
| 03/28/2007 | EP1767641A1 Antigenic neisserial peptides |
| 03/28/2007 | EP1767638A2 Mutation associated with epilepsy |
| 03/28/2007 | EP1767637A1 Mutation associated with epilepsy |
| 03/28/2007 | EP1767619A1 Method of culturing embryonic stem cells with the use of amniotic membrane-origin factor |
| 03/28/2007 | EP1767221A2 Preparation and use of a bivalent vaccine against morphine-heroine addiction |
| 03/28/2007 | EP1767217A1 Agent for promoting the recovery from dysfunction after the onset of central neurological disease |
| 03/28/2007 | EP1767212A1 Usage of the plant of genus ampelopsis and extracts thereof for manufacture of medicament and functional food |
| 03/28/2007 | EP1767211A1 Pharmaceutical agent containing hyaluronan as an active ingredient |
| 03/28/2007 | EP1767210A1 The medical use of paeoniflorin |
| 03/28/2007 | EP1767209A1 Neuroprotective drug |
| 03/28/2007 | EP1767207A2 Solid Oral Dosage Forms |
| 03/28/2007 | EP1767206A2 Solid Oral Dosage Forms |
| 03/28/2007 | EP1767197A2 Treatment of Alzheimer's disease with inhibitors of cell cycle re-entry and progression |
| 03/28/2007 | EP1766009A2 Treatment of neurodegenerative disease through intracranial delivery of sirna |
| 03/28/2007 | EP1765862A2 Heparin binding peptide |
| 03/28/2007 | EP1765861A2 Fgfr binding peptides |
| 03/28/2007 | EP1765850A1 Substituted propane phosphinic acid derivatives |
| 03/28/2007 | EP1765829A1 Tricyclic compounds and their use as mglur1 antagonists |
| 03/28/2007 | EP1765816A1 Substituted 1-propiolylpiperazines having an affinity for the mglur5 receptor in order to treat painful conditions |
| 03/28/2007 | EP1765815A2 New compounds useful for treating cns disorders |
| 03/28/2007 | EP1765805A2 Cgrp receptor antagonists |
| 03/28/2007 | EP1765796A1 Substituted heteroaryl- and phenylsulfamoyl compounds |
| 03/28/2007 | EP1765795A2 Alkynyl derivatives as modulators of metabotropic glutamate receptors |
| 03/28/2007 | EP1765779A1 New substituted piperidines as modulators of dopamine neurotransmission |
| 03/28/2007 | EP1765390A2 Method for preventing and treating alzheimer´s disease |
| 03/28/2007 | EP1765388A2 Combination therapy for preventing or treating alzheimer's disease, and kit therefor |
| 03/28/2007 | EP1765381A1 Treatment of neurological disorders with haematopoietic growth factors |
| 03/28/2007 | EP1765380A1 Method of treating parkinson"s disease in humans by direct infusion of glial cell-line derived neurotrophic factor into the zona incerta |
| 03/28/2007 | EP1765364A1 Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder |
| 03/28/2007 | EP1765324A2 Compositions of stable bioactive metabolites of docosahexaenoic (dha) and eicosapentaenoic (epa) acids |
| 03/28/2007 | EP1765319A1 Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease |
| 03/28/2007 | EP1765313A2 Compounds for immunopotentiation |
| 03/28/2007 | EP1765075A1 Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
| 03/28/2007 | EP1554305B1 Prion protein-binding peptide sequences |
| 03/28/2007 | EP1545552B1 Combination therapy wherein a serotonin reuptake inhibitor is used |
| 03/28/2007 | EP1497294B1 1,2,3,4,7,8-HEXAHYDRO-6 i H /i - 1,4 DIAZEPINO 6,7 ,1- i 1J /i QUINOLINE DERIVATIVES AS ANTIPSYCHOTIC AND ANTI OBESITY AGENTS |
| 03/28/2007 | EP1453836B1 BICYCLIC [1,2,4] -TRIAZOLE ADENOSINE A2a RECEPTOR ANTAGONISTS |
| 03/28/2007 | EP1403371B1 Polypeptide having a cell death inhibitory activity |
| 03/28/2007 | EP1331933B1 Tiagabine for the treatment of diabetic neuropathy |
| 03/28/2007 | EP1152760B1 Use of 4-amino pyridine for treatment of peripheral neuropathies |
| 03/28/2007 | EP1096936B1 Treatment of dyskinesia through mu selective opioid antagonists |
| 03/28/2007 | EP0908182B2 Preventives or remedies for diseases induced by hypofunction of nitric oxide synthase (nos) |
| 03/28/2007 | CN1938308A Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| 03/28/2007 | CN1938300A Oxadiazolone derivatives as PPAR delta agonists |
| 03/28/2007 | CN1938030A Transdermal iontophoretic delivery of piperazinyl-2(3h)-benzoxazolone compounds |
| 03/28/2007 | CN1938018A Use of compounds that are able to increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced igf-1 serum level |
| 03/28/2007 | CN1938013A Methods and agents for inhibiting dynamin-dependent endocytosis |
| 03/28/2007 | CN1938010A Novel use of peptide compounds for treating pain in painful diabetic neuropathy |
| 03/28/2007 | CN1935839A Analogues of glp-1 |
| 03/28/2007 | CN1935808A Long-Chain aromatic piperazine modified duloxetine-like compound, and its preparation and use |
| 03/28/2007 | CN1935807A Aryl piperazine modified benzo [b] thiophene compound, and its preparing method and use |
| 03/28/2007 | CN1935768A Vegeta tive female sex hormone eudesmane compound, and its preparing method and use |
| 03/28/2007 | CN1935260A Human antibodies that bind human tnfalpha |
| 03/28/2007 | CN1935258A West nile vaccine |
| 03/28/2007 | CN1935253A Cerebral proteolysis dispersible tablet and its preparing method |
| 03/28/2007 | CN1935251A Method for preparing Chinese medicine for treating epilepsy |
| 03/28/2007 | CN1935235A Chinese medicine injection preparation and its preparing method |
| 03/28/2007 | CN1935234A Chinese medicine injection preparation and its preparing method |
| 03/28/2007 | CN1935233A Chinese medicine injection preparation and its preparing method |
| 03/28/2007 | CN1935232A Chinese medicine injection preparation and its preparing method |
| 03/28/2007 | CN1935231A Chinese medicine injection preparation and its preparing method |
| 03/28/2007 | CN1935230A Chinese medicine injection preparation and its preparing method |
| 03/28/2007 | CN1935229A Chinese medicine injection preparation and its preparing method |
| 03/28/2007 | CN1935227A Medicine composition for improving sleep |
| 03/28/2007 | CN1935199A Quality control method for Chinese medicine compound preparation |
| 03/28/2007 | CN1935191A External ointment for treating facioplegia |
| 03/28/2007 | CN1935170A Animal medicament with nourishing qi to invigorate spleen, tonifying kidney to relieve mental strain and its preparing method |
| 03/28/2007 | CN1935168A Yuntongding medicine and its production process |
| 03/28/2007 | CN1935165A Moringaceae tablet and its producing method |
| 03/28/2007 | CN1935143A Inhibition of Tau-Tau-association |
| 03/28/2007 | CN1935141A Compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
| 03/28/2007 | CN1935136A Effective fraction medicine for treating parkinson's disease |
| 03/28/2007 | CN1935130A Oral solution containing memantine |